mTIMED SLCT Platform

Metabolites derived from cellular metabolism modulates various cell functions in the respective microenvironments, especially in tumor and immune microenvironments. Excess accumulation or inadequate presence of these metabolites lead to various pathological conditions. Nirogy is focusing on metabolic SLCTs that are exposed to extracellular matrix (ECM) and employing these targets to build the integrated metabolic Tumor and Immune MicroEnvironment Drugs (mTIMED) platform as the discovery engine.

Our exploration begins with identifying a suitable target of interest and building homology models based on known structural data along with in-house mutational studies, and computational capabilities. Once reasonable model is established, we perform virtual screening of compound databases and available tool compounds while developing physiologically relevant proprietary biological assays to identify lead compounds. “Synchronous lead optimization strategy” provides us with rapid identification of few desired advanced leads to test in relevant in vivo mouse models. Translational bioinformatics is used to select relevant mouse models of target indication and mode of action (MOA). With a good understanding of MOA, disease modeling, and biomarkers, patient stratification driven clinical development will be conducted.